Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...

Mixing CD138-positive with CD138-negative cells from the same sample at a ratio of 1:1 can be sufficient to perform OGM. Since OGM typically requires 1 million cells, this finding suggests that as ...

Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA pre-targeted radioimmunotherapy for relapsed non-Hodgkin lymphoma. Y-mAbs Therapeutics, Inc. announced that the first patient has ...